Safety and efficacy of gene replacement therapy for X-linked myotubular myopathy (ASPIRO): a multinational, open-label, dose-escalation trial.
Journal article
Shieh PB. et al, (2023), Lancet Neurol, 22, 1125 - 1139
Clinical and genetic features of patients suffering from CMT4J.
Journal article
Beloribi-Djefaflia S. et al, (2023), J Neurol
Titin copy number variations associated with dominant inherited phenotypes.
Journal article
Perrin A. et al, (2023), J Med Genet
261st ENMC International Workshop: Management of safety issues arising following AAV gene therapy. 17th-19th June 2022, Hoofddorp, The Netherlands.
Journal article
Servais L. et al, (2023), Neuromuscul Disord
First regulatory qualification of a digital primary endpoint to measure treatment efficacy in DMD.
Journal article
Servais L. et al, (2023), Nat Med, 29, 2391 - 2392
Spinal Muscular Atrophy.
Journal article
Oskoui M. and Servais L., (2023), Continuum (Minneap Minn), 29, 1564 - 1584
Tamoxifen in children with Duchenne muscular dystrophy.
Journal article
Servais L., (2023), Lancet Neurol, 22, 872 - 873
Combination disease-modifying treatment in spinal muscular atrophy: A proposed classification.
Journal article
Proud CM. et al, (2023), Ann Clin Transl Neurol
Newborn screening for spinal muscular atrophy - what have we learned?
Journal article
De Siqueira Carvalho AA. et al, (2023), Expert Rev Neurother, 1 - 8
Qualitative Insights into Key Angelman Syndrome Motor Related Concepts Reported by Caregivers-A Thematic Analysis of Semi-Structured Interviews.
Journal article
Rogers M. et al, (2023), Children (Basel), 10
The use of digital outcome measures in clinical trials in rare neurological diseases: a systematic literature review.
Journal article
Poleur M. et al, (2023), Orphanet J Rare Dis, 18
Universal newborn screening for spinal muscular atrophy in Ukraine.
Journal article
Olkhovych N. et al, (2023), Lancet, 402, 288 - 289
Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review.
Journal article
Aragon-Gawinska K. et al, (2023), Genes (Basel), 14
Novel Therapeutic Approaches in Inherited Neuropathies: A Systematic Review.
Journal article
Hustinx M. et al, (2023), Pharmaceutics, 15
Cost-Effectiveness of Newborn Screening for Spinal Muscular Atrophy in England.
Conference paper
Weidlich D. et al, (2023), Neurol Ther
Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA).
Journal article
Oskoui M. et al, (2023), J Neurol
TOR1AIP1-Associated Nuclear Envelopathies.
Journal article
Mackels L. et al, (2023), Int J Mol Sci, 24
Quantitative measures of motor development in Angelman syndrome.
Journal article
Duis J. et al, (2023), Am J Med Genet A
Determining minimal clinically important differences in the North Star Ambulatory Assessment (NSAA) for patients with Duchenne muscular dystrophy
Journal article
Gupta VA. et al, (2023), PLoS ONE, 18
Evolving regulatory perspectives on digital health technologies for medicinal product development.
Journal article
Colloud S. et al, (2023), NPJ Digit Med, 6